Effects of erythropoietin stimulating agent on quality of life in non-dialysis ESRD patients

Phase 4

Completed

• Conditions: Quality of Life; Anemia; Kidney Failure, Chronic; Quality of life in non dialysis chronic kidney disease who receive and not receive erythropoiesis stimulating agent; Hematinics

• Registration Number: TCTR20231103005
• Lead Sponsor: Phayao hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-03
• Study Completion: 2023-11-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

age more than 18 years old
non dialysis chronic kidney disease stage V (eGFR < 15 ml/min/1.73m2)
Hemoglobin 6.0-10.0 g/dL
Transferrin saturation (TSAT) > 20% and ferritin > 100 mg/d

Exclusion Criteria

Prior blood transfusion
Pregnancy
Breast feeding
Iron deficiency anemia (TSAT < 20%, Ferritin < 100 mg/dL)
Hemoglobinopathy
Iron overload
Hemochromatosis
Upper Gastrointestinal bleeding/Acute bleeding in 6 months before
Severe infection
Any stage of malignancy
Severe psychosis problem
Severe systemic disease
Uncontrolled hypertension within 1 month
Cerebrovascular disease within 1 month

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life (EQ-5D-5L and KDQoL) 24 weeks after initiation score

Secondary Outcome Measures

Name	Time	Method
aboratory data 24 weeks after initiation amount